Sickle cell gene-editing treatment poised for FDA approval

POLITICO's Pulse Check

Content provided by POLITICO. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by POLITICO or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

11M ago 6:23

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on September 27, 2024 03:32 (1M ago). Last successful fetch was on August 26, 2024 16:12 (2M ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

The FDA is close to a decision on a landmark one-time gene-editing treatment for patients with sickle cell disease and another blood disorder. Host Kelly Hooper talks with POLITICO health care reporter Lauren Gardner about how the therapy works, its safety profile, who will be eligible for it and the significant challenges around affordability and access.

600 episodes

#News #Health and Well-Being #Health Care #Politico Health #Fooducate Podcasts #Fitness #Politics #Medicine #Poland #POLITICO #POLITICOs Pulse Check #POLITICOs Pulse